去纤苷在医保报销范围内吗？

(also called defibrinated sodium) has anti-thrombosis, promoting fibrinolysis, anti-ischemia, and anti-infection effects in vivo and in vitro. Defibrotide is the first drug approved by the U.S. FDA to treat severe hepatic veno-occlusive disease. It is used for adult or pediatric patients with hepatic vein obstruction (VOD) who have undergone blood or bone marrow hematopoietic stem cell transplantation (HSCT) and are accompanied by renal or pulmonary function abnormalities. The drug has also received "orphan drug" designation. Today we will learn more about whether defibrotide is reimbursed by medical insurance?

Defibrotide (also called defibrotide sodium) has not yet been officially launched in China. Patients in need can purchase the version available abroad. According to Medical Companion Travel, the price of defibrotide is about 22,000. Patients can purchase drugs abroad or obtain drugs through domestic professional overseas medical service organizations (such as Medical Companion Travel), and sign a guarantee contract to guarantee 100% authenticity!

A multi-center randomized phase III clinical trial was completed in Europe. The trial included 356 stem cell transplant patients. The incidence of hepatic vein occlusion 30 days after transplantation was compared. There were 180 patients in the defibrotide group, 2 of whom developed hepatic vein occlusion, accounting for 12%; there were 176 patients in the control group, of which 35 developed hepatic vein occlusion, accounting for 20%. The use of defibrotide significantly reduced the incidence of the disease, and the effect was obvious.

The recommended dose of defibrotide (also called defibrotide sodium) for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Defibrotide was administered for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrotide until resolution of VOD or up to a maximum of 60 days.

The therapeutic effect of defibrotide has attracted the most attention since its launch. The use of heparin in the treatment of diseases such as hepatic venous occlusion often increases the patient's risk of bleeding. However, defibrination alone or in combination with heparin has not only achieved a good effect in preventing HVOD, but also has a very low incidence of side effects.

Defibrotide (also called defibrotide sodium) is a mixture of single-stranded oligonucleotides with anti-thrombotic and fibrinolysis-promoting effects. In recent years, multiple clinical research results have shown that defibrotide is a safe and effective drug for preventing and treating HVOD after HSCT.

The above is the content of medical insurance (also called defibrinated sodium). I hope it can help you!

Recommended related hot articles: /newsDetail/84593.html